CD274 and renal cell adenocarcinoma: Clinical studies that sought to predict the success of RCC treatment solely dependent on PD-L1 expression obtained controversial data or there was no association between expression of the biomarker of interest with the treatment used (Motzer et al. 2015a, b, 2018a; Pignon et al. 2019).